How to buy Cellectis S-A stock | $15.67

Cellectis S.A is a biotechnology business based in the US. Cellectis S-A shares (CLLS) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectis S-A employs 272 staff and has a trailing 12-month revenue of around 0.00.

Cellectis S-A stock price (NASDAQ: CLLS)

Use our graph to track the performance of CLLS stocks over time.

Cellectis S-A shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$15.67
52-week range	$13.13 - $34.71
50-day moving average	$14.92
200-day moving average	$20.09
Wall St. target price	$34.78
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.24

Buy Cellectis S-A shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cellectis S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cellectis S.A by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellectis S-A price performance over time

Historical closes compared with the close of $15.67 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	1.29%
3 months (2021-04-30)	-15.80%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Cellectis S-A financials

Revenue TTM	$58.5 million
Gross profit TTM	$46.2 million
Return on assets TTM	-16.35%
Return on equity TTM	-39.2%
Profit margin	-193.15%
Book value	$6.09
Market capitalisation	$596.1 million

TTM: trailing 12 months

Shorting Cellectis S-A shares

There are currently 1.3 million Cellectis S-A shares held short by investors – that's known as Cellectis S-A's "short interest". This figure is 6.3% up from 1.2 million last month.

There are a few different ways that this level of interest in shorting Cellectis S-A shares can be evaluated.

Cellectis S-A's "short interest ratio" (SIR)

Cellectis S-A's "short interest ratio" (SIR) is the quantity of Cellectis S-A shares currently shorted divided by the average quantity of Cellectis S-A shares traded daily (recently around 263894.76987448). Cellectis S-A's SIR currently stands at 4.78. In other words for every 100,000 Cellectis S-A shares traded daily on the market, roughly 4780 shares are currently held short.

However Cellectis S-A's short interest can also be evaluated against the total number of Cellectis S-A shares, or, against the total number of tradable Cellectis S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellectis S-A's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cellectis S-A shares in existence, roughly 30 shares are currently held short) or 0.0435% of the tradable shares (for every 100,000 tradable Cellectis S-A shares, roughly 44 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellectis S-A.

Find out more about how you can short Cellectis S-A stock.

Cellectis S-A share dividends

We're not expecting Cellectis S-A to pay a dividend over the next 12 months.

Cellectis S-A share price volatility

Over the last 12 months, Cellectis S-A's shares have ranged in value from as little as $13.13 up to $34.71. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectis S-A's is 2.1524. This would suggest that Cellectis S-A's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Cellectis S-A overview

Cellectis S. A. , a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat.

Frequently asked questions

What percentage of Cellectis S-A is owned by institutions?
Currently 43.076% of Cellectis S-A shares are held by institutions. How many people work for Cellectis S-A?
Latest data suggests 272 work at Cellectis S-A. When does the fiscal year end for Cellectis S-A?
Cellectis S-A's fiscal year ends in December. Where is Cellectis S-A based?
Cellectis S-A's address is: 8, rue de la Croix Jarry, Paris, France, 75013 What is Cellectis S-A's ISIN number?
Cellectis S-A's international securities identification number is: US15117K1034 What is Cellectis S-A's CUSIP number?
Cellectis S-A's Committee on Uniform Securities Identification Procedures number is: 15117K103